S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:RXDX

Prometheus Biosciences - RXDX Stock Forecast, Price & News

$109.67
-3.99 (-3.51%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$106.32
$114.51
50-Day Range
$36.06
$121.25
52-Week Range
$21.50
$122.75
Volume
475,838 shs
Average Volume
503,909 shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$117.10

Prometheus Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.8% Upside
$117.10 Price Target
Short Interest
Bearish
10.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Prometheus Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$3.57 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.43) to ($3.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

1028th out of 1,053 stocks

Pharmaceutical Preparations Industry

504th out of 519 stocks


RXDX stock logo

About Prometheus Biosciences (NASDAQ:RXDX) Stock

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Stock News Headlines

Analyst Expectations for Prometheus Biosciences's Future
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Is Prometheus Biosciences a Good Stock to Buy Right Now?
2 Biotech Stocks Options Traders Love Today
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?
See More Headlines
Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Company Calendar

Last Earnings
11/09/2022
Today
2/02/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$117.10
High Stock Price Forecast
$181.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+6.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-90,190,000.00
Net Margins
-1,847.71%
Pretax Margin
-1,847.71%

Debt

Sales & Book Value

Annual Sales
$3.13 million
Book Value
$6.04 per share

Miscellaneous

Free Float
36,456,000
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
-0.52

Key Executives

  • Mr. Mark C. McKenna (Age 42)
    Pres, CEO & Chairman
    Comp: $2.22M
  • Dr. Keith W. Marshall M.B.A. (Age 54)
    MBA, Ph.D., Chief Financial Officer
    Comp: $971.67k
  • Mr. Mark Stenhouse (Age 55)
    Chief Operating Officer
    Comp: $679.71k
  • Dr. Allison Luo M.D. (Age 49)
    Chief Medical Officer
    Comp: $827.97k
  • Dr. Olivier Laurent Ph.D. (Age 50)
    Chief Scientific Officer & Head of R&D
  • Ms. Noel Kurdi
    VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq. (Age 43)
    Gen. Counsel & Sec.
  • Ms. Nori Ebersole (Age 57)
    Chief People Officer
  • Dr. Thierry Dervieux DABCC (Age 54)
    Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director
  • Mr. Chris Doughty
    Chief Bus. Officer













RXDX Stock - Frequently Asked Questions

Should I buy or sell Prometheus Biosciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RXDX shares.
View RXDX analyst ratings
or view top-rated stocks.

What is Prometheus Biosciences' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price objectives for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $55.00 to $181.00. On average, they predict the company's stock price to reach $117.10 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for RXDX
or view top-rated stocks among Wall Street analysts.

How have RXDX shares performed in 2023?

Prometheus Biosciences' stock was trading at $110.00 at the start of the year. Since then, RXDX stock has decreased by 0.3% and is now trading at $109.67.
View the best growth stocks for 2023 here
.

When is Prometheus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our RXDX earnings forecast
.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. The biopharmaceutical company had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.77 million. Prometheus Biosciences had a negative net margin of 1,847.71% and a negative trailing twelve-month return on equity of 61.37%.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Who are Prometheus Biosciences' major shareholders?

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Waypoint Capital Advisors LLC (0.41%), AR Asset Management Inc. (0.12%), New York State Common Retirement Fund (0.09%), Comerica Bank (0.08%), Moody Aldrich Partners LLC (0.03%) and Legato Capital Management LLC (0.02%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Prometheus Biosciences?

Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $109.67.

How much money does Prometheus Biosciences make?

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $4.60 billion and generates $3.13 million in revenue each year. The biopharmaceutical company earns $-90,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.

This page (NASDAQ:RXDX) was last updated on 2/2/2023 by MarketBeat.com Staff